1.           Introduction

1.1         Scope of the Study

1.2         The Insight Partners Research Report Guidance

1.3         Market Segmentation

1.3.1        North America Multiple Sclerosis Therapeutics Market – By Drug Class

1.3.2        North America Multiple Sclerosis Therapeutics Market – By Route of Administration

1.3.3        North America Multiple Sclerosis Therapeutics Market – By Distribution Channel

1.3.4        North America Multiple Sclerosis Therapeutics Market – By Country

2.           Multiple Sclerosis Therapeutics Market – Key Takeaways

3.           Research Methodology

3.1         Coverage

3.2         Secondary Research

3.3         Primary Research

4.           North America Multiple Sclerosis Therapeutics– Market Landscape

4.1         Overview

4.2         PEST Analysis

4.2.1        North America – PEST Analysis

4.3         Expert Opinions

5.           Multiple Sclerosis Therapeutics Market – Key Market Dynamics

5.1         Market Drivers

5.1.1        Growing Prevalence of Multiple Sclerosis (MS)

5.1.2        Rising Funding for Multiple Sclerosis Research

5.2         Market Restraints

5.2.1        High Cost of Multiple Sclerosis Treatment

5.3         Market Opportunities

5.3.1        Increasing Awareness About Multiple Sclerosis

5.4         Future Trends

5.4.1        Development and Launch of Innovative Products

5.5         Impact analysis

6.           Multiple Sclerosis Therapeutics Market – North America Analysis

6.1         North America Multiple Sclerosis Therapeutics Market Revenue Forecast and Analysis

7.           Multiple Sclerosis Therapeutics Market Analysis – By Drug Class

7.1         Overview

7.2         Multiple Sclerosis Therapeutics Market Revenue Share, by Drug Class (2019 and 2027)

7.3         Immunosuppressant

7.3.1        Overview

7.3.2        Immunosuppressant: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

7.4         Immunomodulators

7.4.1        Overview

7.4.2        Immunomodulators: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

8.           Multiple Sclerosis Therapeutics Market Analysis – By Route of Administration

8.1         Overview

8.2         Multiple Sclerosis Therapeutics Market Revenue Share, by Route of Administration (2019 and 2027)

8.3         Injectable

8.3.1        Overview

8.3.2        Injectable: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

8.4         Oral

8.4.1        Overview

8.4.2        Oral: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

9.           Multiple Sclerosis Therapeutics Market Analysis – By Distribution Channel

9.1         Overview

9.2         Multiple Sclerosis Therapeutics Market Share, by Distribution Channel, 2019 and 2027

9.3         Hospital Pharmacies

9.3.1        Overview

9.3.2        Hospital Pharmacies: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

9.4         Retail Pharmacies

9.4.1        Overview

9.4.2        Retail Pharmacies: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

9.5         E-Commerce

9.5.1        Overview

9.5.2        E-Commerce: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

10.        Multiple Sclerosis Therapeutics Market Analysis and Forecast To 2027 – North America Analysis

10.1      North America: Multiple Sclerosis Therapeutics Market

10.1.1     Overview

10.1.2     North America: Multiple Sclerosis Therapeutics Market, by Country, 2019 & 2027 (%)

10.1.3     US: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

10.1.3.1       US: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

10.1.3.2       US: Multiple Sclerosis Therapeutics Market, by Drug Class, 2018–2027 (USD Million)

10.1.3.3       US: Multiple Sclerosis Therapeutics Market, by Route of Administration 2018–2027 (USD Million)

10.1.3.4       US: Multiple Sclerosis Therapeutics Market, by Distribution Channel 2018–2027 (USD Million)

10.1.4     Canada: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

10.1.4.1       Canada: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

10.1.4.2       Canada: Multiple Sclerosis Therapeutics Market, by Drug Class, 2018–2027 (USD Million)

10.1.4.3       Canada: Multiple Sclerosis Therapeutics Market, by Route of Administration 2018–2027 (USD Million)

10.1.4.4       Canada: Multiple Sclerosis Therapeutics Market, by Distribution Channel 2018–2027 (USD Million)

10.1.5     Mexico: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

10.1.5.1       Mexico: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

10.1.5.2       Mexico: Multiple Sclerosis Therapeutics Market, by Drug Class, 2018–2027 (USD Million)

10.1.5.3       Mexico: Multiple Sclerosis Therapeutics Market, by Route of Administration 2018–2027 (USD Million)

10.1.5.4       Mexico: Multiple Sclerosis Therapeutics Market, by Distribution Channel, 2018–2027 (USD Million)

11.        Impact of COVID-19 Pandemic on North America Multiple Sclerosis Therapeutics Market

11.1      North America: Impact Assessment of COVID-19 Pandemic

12.        Industry Landscape

12.1      Overview

12.2      Organic Developments

12.2.1     Overview

12.3      Inorganic Developments

12.3.1     Overview

13.        Company Profiles

13.1      Merck & Co., Inc.

13.1.1     Key Facts

13.1.2     Business Description

13.1.3     Products and Services

13.1.4     Financial Overview

13.1.5     SWOT Analysis

13.1.6     Key Developments

13.2      Novartis AG

13.2.1     Key Facts

13.2.2     Business Description

13.2.3     Products and Services

13.2.4     Financial Overview

13.2.5     SWOT Analysis

13.2.6     Key Developments

13.3      Bayer AG

13.3.1     Key Facts

13.3.2     Business Description

13.3.3     Products and Services

13.3.4     Financial Overview

13.3.5     SWOT Analysis

13.3.6     Key Developments

13.4      Sanofi

13.4.1     Key Facts

13.4.2     Business Description

13.4.3     Products and Services

13.4.4     Financial Overview

13.4.5     SWOT Analysis

13.4.6     Key Developments

13.5      Bristol-Myers Squibb Company

13.5.1     Key Facts

13.5.2     Business Description

13.5.3     Products and Services

13.5.4     Financial Overview

13.5.5     SWOT Analysis

13.5.6     Key Developments

13.6      Horizon Therapeutics plc

13.6.1     Key Facts

13.6.2     Business Description

13.6.3     Products and Services

13.6.4     Financial Overview

13.6.5     SWOT Analysis

13.6.6     Key Developments

13.7      TEVA PHARMACEUTICAL INDUSTRIES LTD

13.7.1     Key Facts

13.7.2     Business Description

13.7.3     Products and Services

13.7.4     Financial Overview

13.7.5     SWOT Analysis

13.7.6     Key Developments

13.8      Takeda Pharmaceutical Company Limited

13.8.1     Key Facts

13.8.2     Business Description

13.8.3     Products and Services

13.8.4     Financial Overview

13.8.5     SWOT Analysis

13.8.6     Key Developments

13.9      F. HOFFMANN-LA ROCHE LTD.

13.9.1     Key Facts

13.9.2     Business Description

13.9.3     Products and Services

13.9.4     Financial Overview

13.9.5     SWOT Analysis

13.9.6     Key Developments

13.10   Biogen

13.10.1  Key Facts

13.10.2  Business Description

13.10.3  Products and Services

13.10.4  Financial Overview

13.10.5  SWOT Analysis

13.10.6  Key Developments

14.        Appendix

14.1      About The Insight Partners

14.2      Glossary of Terms

LIST OF TABLES

Table 1.             US Multiple Sclerosis Therapeutics Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)

Table 2.             US Multiple Sclerosis Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

Table 3.             US Multiple Sclerosis Therapeutics Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)

Table 4.             Canada Multiple Sclerosis Therapeutics Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)

Table 5.             Canada Multiple Sclerosis Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027  (USD Million)

Table 6.             Canada Multiple Sclerosis Therapeutics Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)

Table 7.             Mexico Multiple Sclerosis Therapeutics Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)

Table 8.             Mexico Multiple Sclerosis Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

Table 9.             Mexico Multiple Sclerosis Therapeutics Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)

Table 10.          Organic Developments Done by Companies

Table 11.          Inorganic Developments Done By Companies

Table 12.          Glossary of Terms, Multiple sclerosis therapeutics Market

LIST OF FIGURES

Figure 1.           Multiple Sclerosis Therapeutics Market Segmentation

Figure 2.           Multiple Sclerosis Therapeutics Market Segmentation, By Country

Figure 3.           Multiple Sclerosis Therapeutics Market Overview

Figure 4.           Immunomodulators Segment by Drug Class Held the Larger Share

Figure 5.           North America Multiple Sclerosis Therapeutics Market, by Country (US$ Million)

Figure 6.           North America PEST Analysis

Figure 7.           Multiple Sclerosis Therapeutics Market Impact Analysis of Driver and Restraints

Figure 8.           North America Multiple Sclerosis Therapeutics Market – Revenue Forecast and Analysis – 2019- 2027

Figure 9.           Multiple Sclerosis Therapeutics Market Revenue Share, by Drug Class (2019 and 2027)

Figure 10.        Immunosuppressant: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

Figure 11.        Immunomodulators: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

Figure 12.        Multiple Sclerosis Therapeutics Market Revenue Share, by Route of Administration (2019 and 2027)

Figure 13.        Injectable: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

Figure 14.        Oral: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

Figure 15.        Multiple Sclerosis Therapeutics Market Share, by Distribution Channel, 2019 and 2027

Figure 16.        Hospital Pharmacies: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

Figure 17.        Retail Pharmacies: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

Figure 18.        E-Commerce: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

Figure 19.        North America: Multiple Sclerosis Therapeutics Market, by Key Country – Revenue (2019) (USD Million)

Figure 20.        North America: Multiple Sclerosis Therapeutics Market, by Country, 2019 & 2027 (%)

Figure 21.        US: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

Figure 22.        Canada: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

Figure 23.        Mexico: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

Figure 24.        Impact of COVID-19 Pandemic in North American Country Markets